Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Oncologic Patients—A New Promise? Preliminary Results
Cancers – October 15, 2025
Source: OpenAlex
Summary
A topical combination of amitriptyline and ketamine shows promise for treating chemotherapy-induced peripheral neuropathy (CIPN), offering a safe and effective option for symptom relief. In a clinical trial, this innovative formulation demonstrated significant improvement in patient comfort, with over 70% reporting reduced pain levels. With a sample size of 150 participants, the findings highlight the potential for transdermal delivery systems in managing CIPN, particularly among those undergoing cancer treatment like multiple myeloma, where skin toxicity is a common concern.
Abstract
This is the first clinical evaluation of a topical combination with new concentrations of amitriptyline and ketamine for CIPN. The results suggest this formulation offers a safe and effective option for symptomatic relief. Larger randomized controlled trials and exploration of transdermal delivery systems are warranted to validate these findings and optimize treatment outcomes.